Regular GLP-1 therapy uses higher doses designed primarily for weight loss or diabetes management. Microdosing uses lower doses—typically below the standard starting dose—to activate metabolic pathways without intense appetite suppression. The goal shifts from weight loss to overall metabolic health, inflammation reduction, and longevity support. Side effects are typically milder and the approach is more sustainable long-term.

Tirzepatide is a dual-agonist, meaning it activates both GLP-1 and GIP receptors. This dual action may provide more comprehensive metabolic support than single-pathway GLP-1 medications like semaglutide. GIP helps with insulin sensitivity and fat metabolism, potentially making tirzepatide more effective even at lower doses. Some patients also report better tolerability with tirzepatide.

Most patients report feeling more balanced within the first few weeks—steadier energy, fewer cravings, improved mental clarity, and better sleep. Over 2-3 months, you may notice improvements in metabolic markers like blood sugar stability and inflammatory markers. This is not a weight loss protocol, though some patients experience mild changes in body composition as a secondary effect.

Because microdosing uses lower doses, side effects are typically mild and less frequent than with full-dose therapy. Some patients experience mild nausea, especially in the first week or two. Other possible effects include slight fatigue or injection site reactions. These usually resolve quickly. Serious side effects are rare but should be reported to your provider immediately.

Microdosing is designed for long-term use as part of a comprehensive health optimization strategy. Unlike weight loss protocols with defined endpoints, longevity-focused microdosing can be continued indefinitely with provider oversight. Your provider will monitor your progress and adjust dosing as needed based on your goals and response.